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yahoo.com.cn (J. Zhu).There is increasing evidence that microRNAs (miRNAs) play important roles in cell proliferation,
apoptosis and differentiation that accompany inﬂammatory responses. However, whether miRNAs
are associated with dendritic cell (DC) immuno-inﬂammatory responses to oxidized low density
lipoprotein (oxLDL) stimulation is yet unknown. Our study aims to explore the link of miRNA to
lipid-overload and the immuno-inﬂammatory mechanism for atherosclerosis. Human primary
monocyte-derived DCs were transfected with miR-146a mimics and inhibitor, and then stimulated
by oxLDL. For the ﬂow cytometric analysis of the DC immunophenotype, supernatants were col-
lected to determine inﬂammatory chemokine markers. Our study clearly revealed that miRNA-
146a regulates the maturation process and pro-inﬂammatory cytokine secretion in DCs by targeting
CD40L in ox-LDL-stimulated DCs.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of endogenous, regulatory sin-
gle-stranded RNAs comprising approximately 22 nucleotides. They
suppress gene expression in a sequence-speciﬁc manner, i.e., RNA-
induced silencing complexes, leading to mRNA cleavage and/or
translation repression [1]. MiRNAs are involved in a variety of basic
biological processes, such as cardiogenesis, hematopoietic lineage
differentiation, and oncogenesis [2]. Moreover, bioinformatics anal-
ysis predicts that each miRNA can regulate hundreds of targets,
suggesting thatmiRNAs play an essential role in almost every phys-
iological and pathological pathway [3]. Recent studies have also
shown that miRNAs control diverse aspects of heart disease, includ-
ing hypertrophy, remodeling, heart failure, and arrhythmia [4–11].
MiR-146a, a miRNA, may be involved in innate immunity
through TLR signaling, regulated inﬂammatory response, develop-chemical Societies. Published by E
oRNA; OxLDL, oxidized low
IL, interleukin; UTR, untrans-
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(H. Yan), ting010151452@ment of cancers, and the antiviral pathway. Change in the expres-
sion of miR-146a is an important event in the pathogenesis of
many human diseases, including autoimmune disorders such as
rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis
[12–16], virus infection, multiple cancer, muscle disorders, and
myelodysplastic syndrome. Findings indicate that miR-146a can
also be used as a potential biomarker for disease diagnosis, preven-
tion, and treatment. However, despite numerous studies showing
the introduction of miR-146a expression by pro-inﬂammatory
mediators, there is still little information about its role in athero-
sclerosis and its potential mechanism of action.
Atherosclerosis is now recognized as a chronic lipid-related
inﬂammatory disease where immune mechanisms play a pivotal
role. In the last decade, dendritic cells (DCs) positioned at the inter-
face of the innate and adaptive immune systems have been identi-
ﬁed in atherosclerotic plaques and are considered to play an
important role in atherogenesis [17]. Furthermore, the molecular
mechanisms that regulate gene expression in atherosclerosis are
still not completely understood. Speciﬁcally, relatively little is
known about the role of miRNAs in atherosclerosis, particularly
in its immuno-inﬂammation mechanism.
Our previous study [18] showed the association of miR-146a
with ox-LDL-treated monocytes. Therefore, the aim of the present
study is to investigate the potential role of miR-146a inlsevier B.V. All rights reserved.
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and its potential target in DCs to provide new therapeutic strate-
gies for the treatment or prevention of atherosclerosis.
2. Materials and methods
This investigation conformed to the principles outlined in the
Declaration of Helsinki in the use of human blood and was ap-
proved by the Ethics Committee of Experimental Research, Zhe-
jiang University.
2.1. Human primary peripheral blood DC culture
Peripheral human blood was obtained from healthy donors,
mononuclear cells were isolated by density gradient centrifugation
using Histoplaque 1077 (Sigma, USA). The pure monocytes (over
98%) were obtained using anti-CD14 microbeads (Milteny Biotech,
USA) and seeded into 6-well plates, monocytes were around 90%
pure as assessed by CD14 labeling, then cells (monocytes)
were co-cultured with 1000 units/ml granulocyte GM-CSF and
1000 units/ml interleukin-4 (IL-4) for 5–7 days to obtain the
immature DCs, cells were cultured in a complete medium (RPMI
1640 with 10% fetal calf serum). Oxidized low density lipoprotein
(oxLDL) (30 lg/ml) was added at day 5 and cells were harvested
at day 7.
2.2. Small RNA transfection
MiR-146a mimics and inhibitor were transfected into DCs using
the fast transfection protocol recommended for Hiperfect transfec-
tion reagent (Qiagen) at a ﬁnal concentration of 75 nM (DCs). To
conﬁrm the efﬁciency of transfection, the same amount of Cy3-la-
beled negative control (Darmacon) was also transfected. SiCD40L
and siNS (not signiﬁcant) duplex were synthesized by Dharmacon
RNAi Technologies. All cells were incubated with small RNA for 6 h
and then exposed to ox-LDL for 24 h.
2.3. Flow cytometry
DCs were transfected with small RNA for 6 h; ox-LDL was
added; and the cells were incubated for 24 h. Adherent cells were
harvested, washed once with phosphate-buffered saline, and were
counterstained immunophenotypically for anti-CD80, anti-CD86,
anti-CD40, anti-HLA-DR, and anti-209. Analysis was performed
on a FACS Calibur ﬂow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA) using the Cell Quest Pro software.
2.4. ELISA assays of adhesion markers and chemokine receptors
DCs were transfected with small RNA for 6 h and then incubated
with ox-LDL for another 24 h. The culture supernatant was ana-
lyzed using Sandwich Enzyme Immunoassay kits (R&D Systems
Europe Ltd., Abingdon, UK) according to the manufacturer’s
instructions to determine tumor necrosis factor-a (TNF-a)
and IL-6.
2.5. mRNA and miRNA real-time quantitative polymerase chain
reaction (PCR)
To detect miRNAs from cells, total RNA was isolated using the
mirVana miRNA isolation kit (Ambion) according to the protocol
of the manufacturers. Total and miRNA-speciﬁc cDNA was gener-
ated with iScript cDNA synthesis kit (Bio-Rad), and mirVana quan-
titative RT-PCR primer sets for miR-146a. The PCR reaction was
directly monitored by the ABI PRISM 7000 Sequence DetectionSystem (Applied Biosystems, CA). Brieﬂy, cDNA was made from en-
riched miRNA using the TaqMan MicroRNA RT Kit. U6 RNA was
used as an endogenous control.
This step was performed after DCs with ox-LDL were incubated
for 24 h. mRNA levels were analyzed using the SYBR-GREEN re-
agent kits with gene speciﬁc primers on the Applied Biosystems
7000 real-time PCR system according to the manufacturer’s
instructions. Speciﬁc fragments were ampliﬁed. As an internal
standard, human glyceraldehyde 3-phosphate dehydrogenase
was also ampliﬁed.
2.6. Western blot analysis
The protein extracts were denatured. The solubilized proteins
(20 lg) were subjected to electrophoresis on 10% polyacrylamide
SDS gels and then transferred onto polyvinylidene diﬂuoride mem-
branes (Millipore, MA). This step was followed by probing using
primary antibodies for rabbit anti-human-CD40L (diluted 1:1000
in TBST) or rabbit anti-actin (diluted 1:5000 in TBST) for 2 h, and
then goat anti-rabbit secondary antibody labeled with far-red-ﬂuo-
rescent Alexa Fluor 680 dye. All signals were detected by Odyssey
(Li-cor, USA). Densitomety was performed using Quantity One
(Bio-Rad) to scan the signals.
2.7. Cloning of 30-UTR of CD40L mRNA and reporter gene assay
EST clones containing 30-untranslated region (30-UTR) se-
quences from CD40L cDNA were commercially obtained (Invitro-
gen, Carlsbad, CA, USA) and used as templates for PCR. The
ampliﬁed PCR product was gel-puriﬁed and subcloned into pGL3
(Promega). The insert was excised with Fast Digest Hind III and
Sac I restriction enzymes (Fermentas, Hanover, MD) and then
gel-puriﬁed and ligated into the pGL3 miRNA luciferase reporter
vector (Promega). 293T cells were co-transfected with p-CD40L
UTR miRNA luciferase reporter vector and anti/pre-miR-146a using
lipofectamine 2000 (Invitrogen). Cells were also transformed by
the PGL3-control vector, which is useful in monitoring transfection
efﬁciency. Anti-miR-negative, a miRNA non-homologous to the hu-
man genome, was used as control. All cells were transfected with
pRL-TK (Promega) for normalization control. After 48 h, cells were
washed and lysed with passive lysis buffer. Fireﬂy luciferase activ-
ity was determined using the dual-luciferase reporter assay system
and a luminometer. Relative reporter activity was obtained by nor-
malizing the Renilla control luciferase activity of the controls.
2.8. Statistical analysis
Data are expressed as mean ± S.D. Differences were compared
by t-test and ANOVA. A value of P < 0.05 was considered statisti-
cally signiﬁcant. All experiments were performed at least three
times.
3. Results
3.1. Increased expression of miR-146a in oxLDL-treated DCs
Multiple reports on a role of miR-146a in the regulation of in-
nate and adaptive immune response, for example, Taganov et al.
[22] showed that miR-146a is quickly induced upon activation of
monocytes and we previously found that miR-146a was upregu-
lated in oxLDL-treated monocyte, 18 thus we investigated if oxLDL
could have the effect on miR-146a in DCs, After stimulation with
oxLDL, miR-146a levels increased 3-fold in DCs (Fig. 1A), suggest-
ing a role of miR-146a in immuno-inﬂammatory response by
oxLDL. Next we modulated miR-146a levels in DCs, transfection
Fig. 1. (A) miR-146a expression was increased in DCs upon 24 h of oxLDL stimulation. (B) DCs were transfected with 75 nM pre-miR-146a, anti-miR-146a or pre-miR-neg,
anti-miR-neg. MiR-146a expression was detected by Taqman MicroRNA real-time PCR. Effects of miR-146a on DC maturation. DCs were treated with miR-146a inhibitor or
mimics for 6 h by electroporation and then co-cultured with ox-LDL for 24 h. The co-stimulatory molecules CD80, CD86, and CD40 were detected by FACS for each condition.
(C)The maturation molecules CD80, CD86, and CD40 were regulated by miR-146a (FACS analysis; n = 5, ⁄P < 0.05 vs. the ‘‘pre-neg’’ group, #P < 0.05 compared with the ‘‘anti-
neg’’ group). (D) The relative mRNA level of CD80, CD86, and CD40.
Fig. 2. Effects of miR-146a on DC inﬂammatory response. DCs were incubated in the absence or presence of the miR-146a mimics/inhibitor for 6 h and then incubated with
ox-LDL for 24 h. TNF-a and IL-6 expressions were regulated after the incubation of miR-146a mimics and inhibitor. (A) The relative mRNA level of TNF-a and IL-6. The protein
level of TNF-a(B) and IL-6(C) is detected by ELISA. Mean ± S.D. was calculated from ﬁve different experiments. ⁄P < 0.05 vs. the ‘‘pre-neg’’ group. #P < 0.05 vs. the ‘‘anti-neg’’
group.
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level (Fig. 1B) compared to anti-miR-146a or neg-miR transfection.
3.2. Effects of miR-146a on the maturation and differentiation of DCs
DC maturation is linked to the progression of atherosclerosis.
Immature DCs in the periphery take up antigens efﬁciently but ex-press low levels of MHC and co-stimulatory molecules such as
CD40, CD80, and CD86. However, upon maturation, DCs signiﬁ-
cantly augment their ability to stimulate naïve T cells through
the surface exposure of antigen/MHC complexes and the upregula-
tion of CD40 and other co-stimulatory molecules. Results of this
study conﬁrm that miR-146 partly induces the maturation of
monocyte-derived DCs. The mRNA (Fig. 1D) and protein levels
Fig. 3. Veriﬁcation of the potential target genes (CD40L) of miR-146a by luciferase reporter assay concurrent with the mRNA and protein expression levels. (A) CD40L mRNA
expression was measured by real-time PCR. (B and C) Western blot results of CD40L expression. (D) Cells were co-transfected with p-CD40L-UTR, pGL-3 control, and either
negative control anti-miR or anti-miR-146a, pre-miR-146a, or negative control pre-miR. Luciferase values were normalized by the Renilla control luciferase activity. The ratio
of luciferase activity of each construct was calculated by a luminometer. Data were obtained from three independent experiments. ⁄P < 0.05 vs. the ‘‘pre-neg’’ group. #P < 0.05
vs. the ‘‘anti-neg’’ group.
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and CD86) of ox-LDL-treated DCs were upregulated in response
to incubation with miR-146a inhibitor, meanwhile down-regulated
in response to miR-146a mimics for 24 h. However, no interference
by CD209 and HLA-DR was detected (data not shown), indicating
that miR-146a could partly regulate the maturation of ox-LDL-
treated DCs.
3.3. Regulation of inﬂammatory cytokine secretion by miR-146a
After 24 h, inﬂammatory molecules (i.e., IL-6 and TNF-a) from
DCs exposed to miR-146a inhibitor/mimics were measured. As
shown in Fig. 2, pre-miR-146a decreased some inﬂammatory cyto-
kine (IL-6 and TNF-a) secretions in ox-LDL-induced DCs, whereas
anti-miR-146a increased their secretion both at mRNA level
(Fig. 2A) and protein level (Fig. 2B and C). These ﬁndings suggest
that miR-146a transfection affects the inﬂammatory response in
ox-LDL-treated DCs.
3.4. Repression of CD40L transcription and protein expression by miR-
146a
To verify the predictions and to study the functional conse-
quences of miR-146a, THP-1 cell and DCs were transfected with
anti-miR-146a and pre-miR-146a, and the human CD40L mRNA
and protein levels were quantiﬁed by TaqMan real-time PCR
(Fig. 3A) and Western blotting (Fig. 3B and C). Anti-miR-146a sig-
niﬁcantly induced CD40L mRNA expression, whereas pre-miR-
146a inhibited its expression. There was an accompanying change
in the expression of proteins in the anti-/pre-miR group. These re-
sults strongly suggest that CD40L is among the target genes of miR-
146a.3.5. miR-146a responsiveness of CD40L 30-UTRs
To determine the target genes of miR-146a, candidates were
identiﬁed using bioinformatics tools in several databases (i.e., tar-
getscan4.1, PicTar, and miRanda). These tools veriﬁed that CD40L is
a possible target gene of miR-146a. Thus, CD40L 30-UTRs were sub-
cloned immediately downstream from the ﬁreﬂy luciferase gene.
293T cells were then co-transfected with the miR-146a mimics
and inhibitor, CD40L-UTR. The relative luciferase activities were
then determined. The reporter gene assay showed that, compared
with that in pGL3-CD40L-30-UTR plasmid co-transfected cells, the
activity in cells co-transfected with the anti-miR-146a, and pre-
miR-146a markedly increased and decreased (Fig. 3D; P < 0.01).
This ﬁnding suggests that miR-146a directly targets CD40L.
3.6. CD40L as a functional gene target involved in the miR-146a-
mediated inﬂammatory effect on ox-LDL-induced DCs
Given the results above on CD40L regulation by miR-146a at
both the RNA and protein levels, and the known pro-inﬂammatory
role of CD40L, we speculate that CD40L could be functionally
important targets of miR-146a. To investigate the biological impor-
tance of CD40L as a target of miR-146a, we depleted the DCs of the
CD40L protein by siRNA and assayed the effect of miR-146a inhibi-
tion. The elimination of CD40L expression by siRNA treatment efﬁ-
ciently repressed the CD40L mRNA (Fig. 4A) and protein levels
(Fig. 4B and C), meanwhile, siCD40L could decreased the IL-6
(Fig. 4D and TNF-a Fig. 4E) secretion, both at protein and mRNA le-
vel (Fig. 4F). These effects are similar to those of pre-miR-146a on
ox-LDL-treated DCs. The anti-miR-146a-mediated effect on the
inﬂammatory response of DCs was counteracted through the inhi-
bition of CD40L by siCD40L on ox-LDL-stimulated cells, both at
Fig. 4. Effect of CD40L-speciﬁc knockdown on DCs; CD40L is a functional target gene involved in miR-146a-mediated inﬂammatory response. Conﬁrmation of siRNA-induced
knockdown of CD40L mRNA by qPCR (A) and protein level by western blot (B and C). After the transfection of a small interference RNA for CD40L (siCD40L) or an insigniﬁcant
control sequence (sineg) in ox-LDL-induced DCs, the culture supernatants were analyzed for TNF-a and IL-6 (D and E). (F) The mRNA level of TNF-a and IL-6. The miR-146a-
mediated pro-inﬂammatory cytokine secretion effect was attenuated in ox-LDL-induced DCs through a small interference RNA for CD40L (G-I). Data are presented as
mean ± S.D., n = 3, and ⁄P < 0.05 compared with sineg. #P < 0.05 compared with pure anti-miR-146a group.
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suggest the essential role of CD40L in miR-146a-mediated inﬂam-
matory effects on ox-LDL-induced DCs.
3.7. CD40L as a functional gene target involved in the miR-146a-
mediated cell maturation in ox-LDL-induced DCs
CD40-CD40L co-stimulatory signaling plays a crucial role in DC
function. In vitro, the attachment of CD40 on the surface of DCs by
soluble CD40L or CD40L-transfected L cells stimulates DCs to in-
crease the expression of co-stimulatory molecules, adhesion, and
MHC molecules [31]. We believe that in DCs, the CD40-CD40L
pathway in relation to atherosclerosis could be a promising target
to study. By ﬂow cytometry analysis, we conﬁrmed that inhibiting
CD40L by siRNA treatment efﬁciently repressed some co-stimula-
tory molecule (CD40, 80, 86) expression and the changes in the
anti-miR-146a mediated effect on those co-stimulatory molecules
are attenuated through the inhibition of CD40L by siCD40L, both at
protein (Fig. 5A and B) and mRNA level (Fig. 5C).
4. Discussion
Over the past few years, there have been reports on the role of
miRNAs as regulators of cardiovascular diseases. However, rela-
tively little is known about how miRNAs regulate atherosclerosis,
particularly in the immuno-inﬂammatory mechanism. Ox-LDL
has long been recognized as an interesting feature of early athero-
sclerosis; it eventually undergoes secondary necrosis to form the
lipid core of advanced atherosclerotic plaques [19–21]. The aim
of this study is to link miRNA regulation to the lipid overload
and immuno-inﬂammatory mechanism for atherosclerosis.Previously, changes in miRNA expression proﬁles in monocytes
and macrophages induced by ox-LDL were reported. However, in
this present report, the oxLDL-induced miRNA was analyzed in
DCs. A distinct expression pattern was observed for ox-LDL-in-
duced miRNA; miR-146a persisted for the different expressions,
both in monocytes/macrophages and in DCs. Several studies have
linked miR-146a to NF-KB signaling within the innate immune sys-
tem [22–26]. The regulation of IRAK-1 and TRAF6 by miR-146a has
been characterized [27] and conﬁrmed in some subsequent stud-
ies. PBMCs’ miR-146a expression has also been reported to corre-
late with the active disease RA [12]. However, Li et al. [28]
showed that the expression of miR-146a in PBMCs from patients
with stable angina decreases signiﬁcantly compared with healthy
controls but increases signiﬁcantly in patients with acute coronary
syndrome. These ﬁndings indicate that miR-146a may also have
the potential to become a biomarker for cardiovascular disease
diagnosis. The new data in this report are focused on deﬁning
the functional roles of miR-146a in the maturation and inﬂamma-
tory response of ox-LDL-stimulated DC and its new target, CD40L.
CD40L, as the ligand for CD40, is a member of the tumor necrosis
factor family of cell surface interaction molecules. CD40L is a key
signaling molecule that determines the inﬂammatory or immune
response on the vast majority of immune cells (i.e., lymphocytes,
monocytes, DCs, neutrophils, andmast cells) and non-immune cells
[29–31]. Inhibition of the CD40-CD40L pathway is an attractive
therapeutic target that reduces the clinical complications of athero-
sclerosis. Platelet CD40L/sCD40L could play a decisive and central
role in the inﬂammatory process of atherosclerosis by orchestrating
both the activation and recruitment of different leukocyte subsets
to the vessel wall. However, little is known about how CD40L tran-
scripts are regulated at the post-transcriptional level. Moreover, the
Fig. 5. CD40L is a functional target gene involved in miR-146a-mediated DCmaturation stimulated by ox-LDL. (A) After the transfection of a small interference RNA for CD40L
(siCD40L) or an insigniﬁcant control sequence (sineg) in oxLDL-induced DCs, the co-stimulatory molecules (i.e., CD80, CD86, and CD40) were analyzed by FACS. Meanwhile,
the anti-miR-146a-mediated DC maturation effect was attenuated in oxLDL-induced DCs through a small interference RNA for CD40L. (B) Mean ﬂuorescence intensity
Expression of CD80, CD86, CD40. Values (mean ± S.D.) are calculated from ﬁve different experiments. (C) mRNA level of CD80, CD86, and CD40. Data are presented as
mean ± S.D., n = 5, and ⁄P < 0.05 compared with sineg. #P < 0.05 compared with pure anti-miR-146a group.
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scribed. Based on a computational analysis, we hypothesize that
CD40L can be a target gene of miR-146a. This hypothesis is sup-
ported by the following ﬁndings. First, we found that anti-miR-
146a increases CD40L expression, and pre-miR-146a decreases
CD40L expression at the mRNA and protein levels both in DCs and
THP-1 cells. Second, luciferase reporter assay analysis supports
the theory that the CD40L gene is one of the direct targets of miR-
146a.
Although we conﬁrmed that CD40L is a target gene of miR-
146a, the targets of miR-146a were not linked to DC maturation
and inﬂammatory response. To elucidate their mechanism of
action, we conducted some studies to elucidate whether changes
in miR-146a expression are functionally linked to DC maturation
and the release of inﬂammatory mediators, and investigated
whether the effects of miR-146a on DC maturation and inﬂamma-
tory response are mediated by CD40L. Inhibiting CD40L expres-
sion is predicted to have the same effect as overexpressing
miR-146a.
In our study, we found that miR-146a could partly stall DC mat-
uration and decrease the pro-inﬂammatory cytokine secretion. The
down-regulation of CD40L by either miR-146a overexpression or
inhibition of CD40L activity by siRNA had similar effects. The
depletion of CD40L by siRNA transfection partly reduced the in-
duced DC maturation and cellular pro-inﬂammatory cytokine
secretion upon miR-146a inhibition in DCs. Results suggest that
miR-146a has a negative effect on the maturation and pro-inﬂam-
matory cytokines secretion of ox-LDL-mediated DCs and that
CD40L is an important functional target of miR-146a in this model.
The mechanism is described as follows. CD40L is the target of
miR-146a. When CD40L binds to CD40, the latter is internalized
into the membrane-associated lipid raft fraction, where the bind-ing of TRAF1/2/3/5 and/or TRAF6 occurs. This is followed by the
activation of NF-KB and subsequent induction of inﬂammatory re-
sponse, where they can exert pro-atherogenic functions [32,33].
Donners et al. identiﬁed TRAF6 as the key player in CD40L signaling
and revealed that TRAF6 is important in DC maturation. MiR-146a,
IL-6, and TNF-a are all considered to be regulated by the multiple
pro-inﬂammatory transcription factors, including NF-jB. Thus, the
functional inﬂuence of miR-146a in DC maturation and inﬂamma-
tory response is probably due to the effect of CD40L.
In short, we identiﬁed a novel mechanism for the negative feed-
back regulation of the maturation and inﬂammation of DCs by
demonstrating that the ox-LDL-induced increases in miRNA-146a
expression negatively regulate the pro-inﬂammatory cytokine re-
lease and maturation of DCs. More importantly, this ﬁnding was
observed in oxLDL-induced DCs, indicating that it could be an
important negative feedback mechanism in the atherosclerosis im-
muno-inﬂammatory mechanism. Signiﬁcantly, our results high-
light the role of the target gene CD40L in its responses to miR-
146a interaction, providing a novel therapeutic approach to the
treatment of atherosclerosis.Funding
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